Our pipeline

Current products under development

Products

Preclinical

Phase 1

Phase 2

PTI5803

First in Class candidate (2 patents, 2017 & 2023)

Orphan paediatric syndrome

Other orphan epilepsies

New Leads

New Chemical Entities (1 patent 2024)

Focal epilepsy

Multiple sclerosis

Oter CNS diseases

A clinical stage candidate and NCEs with high therapeutic potential

Positive Phase 1 with PTI5803

Validation of safety
Confirmation of long release profile of our innovative paediatric formulation
Biomarkers related to target engagement

Proprietary New Chemical Entities

New scaffold identified using AI & unique biological models
High therapeutic potential for several neurological and psychiatric disorders

New Specific Target

Pannexin-1 channel are overexpressed only in pathological tissue
Pannexin-1 channel are activated during seizure process

New Safer Target

Blocking activated panx1 does not affect basal brain activity
Already clinical data demonstrating the safety even in children

Ref: Dossi et al., 2018 – Science Transl Med ; Michalski et al., 2020 – Elife ; Dossi et al., 2021 – Purinergic Signal